BIO Bio-Rad Laboratories, Inc. Class A Common Stock
$299.65
Price · Jun 26, 2026
Fundamentals as of Apr 30, 2026
52W Range
$237–$343
59% of range
Analyst Rating
BUY
10 analysts
Price Target
$297
P/E (TTM)
—
ROE
—
Net Profit Margin
—
BIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$299.64
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$237 – $343
BIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
BIO
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
BIO
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
BIO
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
BIO
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
BIO
Peer Median
BIO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
BUY
10 analysts
- Strong Buy 1 10.0%
- Buy 4 40.0%
- Hold 4 40.0%
- Sell 1 10.0%
- Strong Sell 0 0.0%
12-Month Price Target
5 analysts · 2026-06-26
Median
$300.00
Now
$299.64
Low
$275.00
High
$320.00
Median target
$300.00
+0.1%
Mean target
$297.00
-0.9%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
0.31%
Next Report
Jul 29, 2026
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $1.89 | $2.00 | -0.11% |
| Dec. 31, 2025 | $2.51 | $2.73 | -0.22% |
| Sept. 30, 2025 | $2.26 | $1.95 | 0.31% |
| June 30, 2025 | $2.61 | $1.75 | 0.86% |
| March 31, 2025 | $2.54 | $1.83 | 0.71% |
Peer Comparison Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BIO | — | — | — | — | — | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| BRKR | $7.17B | -314.1 | 2.1% | -0.25% | -0.40% | 45.9% |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| AVTR | $7.82B | -14.7 | -3.4% | -8.1% | -8.9% | 32.6% |
| SHC | $5.02B | 65.3 | 5.7% | 6.7% | 14.0% | 55.5% |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
| ADPT | $2.50B | -41.6 | 54.8% | -21.5% | -28.2% | — |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement 16
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Revenue | $592M | $585M | |
| Cost of Revenue | $283M | $279M | |
| Gross Profit | $309M | $306M | |
| R&D Expense | $63M | $74M | |
| SG&A Expense | $212M | $209M | |
| Operating Income | $34M | $24M | |
| Interest Expense | $12M | $12M | |
| Other Non-op | $24M | $37M | |
| Pretax Income | $-690M | $83M | |
| Income Tax | $-163M | $19M | |
| Net Income | $-527M | $64M | |
| EPS (Basic) | $-19.55 | $2.29 | |
| EPS (Diluted) | $-19.55 | $2.29 | |
| Shares (Basic) | 26,958,000 | 27,941,000 | |
| Shares (Diluted) | 26,958,000 | 27,955,000 | |
| EBITDA | $34M | · |
Balance Sheet 23
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Cash & Equivalents | $507M | · | |
| Short-term Investments | $1.06B | · | |
| Receivables | $426M | · | |
| Inventory | $770M | · | |
| Prepaid Expense | $150M | · | |
| Other Current Assets | $31M | · | |
| Current Assets | $2.94B | · | |
| Goodwill | $577M | · | |
| Intangibles | $167M | · | |
| Total Assets | $9.79B | · | |
| Accounts Payable | $133M | · | |
| Current Liabilities | $917M | · | |
| Capital Leases | $139M | · | |
| Deferred Tax | $882M | · | |
| Other Non-current Liabilities | $198M | · | |
| Total Liabilities | $2.94B | · | |
| Long-term Debt | $1.20B | · | |
| Total Debt | $803M | · | |
| Paid-in Capital | $490M | · | |
| Retained Earnings | $7.65B | · | |
| AOCI | $-235M | · | |
| Stockholders' Equity | $6.85B | · | |
| Liabilities + Equity | $9.79B | · |
Cash Flow 14
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Stock-based Comp | $15M | $15M | |
| Amort. of Intangibles | $6M | $5M | |
| Operating Cash Flow | $108M | $130M | |
| CapEx | $30M | $34M | |
| Investing Cash Flow | $-93M | $3M | |
| Net Debt Issued | $-100.0K | · | |
| Stock Issued | $3M | $4M | |
| Stock Repurchased | $48M | $102M | |
| Net Stock Activity | $-44M | · | |
| Financing Cash Flow | $-44M | $-98M | |
| Net Change in Cash | $-23M | $33M | |
| Taxes Paid | $11M | $8M | |
| Free Cash Flow | $78M | · | |
| Levered FCF | $69M | · |
Profitability 8
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Gross Margin | 52.2% | · | |
| Operating Margin | 5.8% | · | |
| Net Margin | -89.0% | · | |
| Pretax Margin | -116.5% | · | |
| EBITDA Margin | 5.8% | · | |
| ROA | -5.5% | · | |
| ROE | -7.8% | · | |
| ROIC | 0.34% | · |
Liquidity & Solvency 5
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Current Ratio | 3.2 | · | |
| Quick Ratio | 2.2 | · | |
| Debt / Equity | 0.1 | · | |
| LT Debt / Equity | 0.1 | · | |
| Interest Coverage | 2.8 | · |
Efficiency 3
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Asset Turnover | 0.1 | · | |
| Inventory Turnover | 0.4 | · | |
| Receivables Turnover | 1.4 | · |
Valuation (TTM) 4
| Metric | Trend | Q1 2026 | Q1 2025 |
|---|---|---|---|
| Revenue TTM | $2.48B | · | |
| Net Income TTM | $-487M | · | |
| P/E | -15.2 | · | |
| Earnings Yield | -6.6% | · |
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.